Page last updated: 2024-12-07

fr 41565

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine: synthetic cpd; also immunoactive peptide isolated from Streptomyces active against multiplication of HSV-1 & HSV-2 virus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115204
MeSH IDM0118331

Synonyms (19)

Synonym
fr-41565
n-[n2-(n-heptanoyl-.gamma.-d-glutamyl)-meso-2(l),2'-(d)-diamino-1-pimeloyl]-d-alanine
(2r,6s)-2-amino-6-[[(4r)-4-(heptanoylamino)-5-hydroxy-5-oxo-pentanoyl]amino]-7-[[(1r)-2-hydroxy-1-methyl-2-oxo-ethyl]amino]-7-oxo-heptanoic acid
fk-565
d-alanine, n-(1-oxoheptyl)-d-g-glutamyl-(6r)-6-carboxy-l-lysyl-
79335-75-4
n-(1-oxoheptyl)-d-gamma-glutamyl-(6r)-6-carboxy-l-lysyl-d-alanine
fr 41565
fk 565
d-alanine, n-((r)-6-carboxy-n2-(n-(1-oxoheptyl)-d-gamma-glutamyl)-l-lysyl)-
heptanoyl-gamma-d-glutamyl-l-meso-diaminopimelyl-d-alanine
d-alanine, n-(1-oxoheptyl)-d-gamma-glutamyl-(6r)-6-carboxy-l-lysyl-
hd9kde59zr ,
unii-hd9kde59zr
DTXSID10229629
d-alanine, n-(1-oxoheptyl)-d-.gamma.-glutamyl-(6r)-6-carboxy-l-lysyl-
heptanoyl-.gamma.-d-glutamyl-(l)-meso-diaminopimelyl-(d)-alanine
(2r,6s)-2-amino-7-[[(1r)-1-carboxyethyl]amino]-6-[[(4r)-4-carboxy-4-(heptanoylamino)butanoyl]amino]-7-oxoheptanoic acid
fr41565

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"The effects of route and starting time of administration on FK-565 inhibition of splenomegaly by Friend leukemia virus (FLV) were studied in mice, and the concomitant effect of FK-565 in allowing reduction of zidovudine dosage was estimated."( Inhibitory effect of FK-565 alone and in combination with zidovudine on retroviral infection by Friend leukemia virus in mice.
Mine, Y; Wakai, Y; Watanabe, Y; Yokota, Y, 1988
)
0.27
" The killing ability of macrophages and polymorphonuclear leukocytes of the immunosuppressed mice was also markedly enhanced by dosing with FK-156."( Immunoactive peptides, FK-156 and FK-565. II. Restoration of host resistance to microbial infection in immunosuppressed mice.
Goto, S; Kuwahara, S; Mine, Y; Nishida, M; Wakai, Y; Watanabe, Y; Yokota, Y, 1983
)
0.27
" When FK-565 and related compounds were encapsulated in multilamellar (MLV) liposomes composed of phosphatidylcholine and phosphatidylserine, dose-response experiments showed that they were about 800 times more effective than the free compounds in activating AM."( Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic state.
Mutsuura, S; Ogawara, M; Sone, S; Tsubura, E; Utsugi, T, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (37.04)18.7374
1990's20 (37.04)18.2507
2000's4 (7.41)29.6817
2010's10 (18.52)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.41 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.51%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (96.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]